Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04295759
Recruitment Status : Recruiting
First Posted : March 4, 2020
Last Update Posted : May 28, 2020
Sponsor:
Information provided by (Responsible Party):
Pediatric Brain Tumor Consortium

Brief Summary:
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Anaplastic Astrocytoma Anaplastic Oligodendroglioma DIPG High-grade Astrocytoma NOS CNS Primary Tumor, NOS (Malignant Glioma) Drug: INCB7839 Phase 1

Detailed Description:

INCB7839 is an inhibitor of the ADAM (A Disintegrin and Metalloprotease) 10 and 17 proteases. Neuronal activity regulates glioma growth through neuroligin-3 (NLGN3). ADAM 10 is the protease responsible for NLGN3 release into the tumor microenvironment and represents a promising therapeutic target.

Pre-clinical studies of INCB7839 in patient-derived pediatric high-grade gliomas (GBM and DIPG) revealed that INCB7839 inhibits pediatric high- grade glioma growth and improves overall survival. In vivo testing also demonstrated that INCB7839 penetrates brain tissue sufficient to achieve its pharmacodynamic effect of ADAM10 inhibition. Further pre-clinical studies in other animals revealed minimal toxicity, including non-adverse to mild increases in serum hepatobiliary enzymes, protein, calcium, cholesterol values, along with minimal decreases in RBC mass parameters; all parameters recovered.

INCB7839 has been evaluated in Phase I and Phase II clinical trials for previously treated solid tumors and breast cancer. Of the adverse events (AEs) noted, the majority were mild-to-moderate in severity, the most frequent being fatigue, nausea, anorexia, diarrhea, emesis, abdominal pain, anemia and constipation. The dose-limiting toxicity for monotherapy with INCB7839 in Phase I clinical trials was declared to be deep venous thrombosis (DVT). Out of 41 patients, there was a total of 9 thrombotic events including mild superficial thrombophlebitis (n=1), DVT (n=4), vena cava thrombosis with renal insufficiency in a patient with squamous cell cancer of the head and neck (n=1), atrial thrombosis in patient with breast cancer (n=1), and pulmonary embolism in patients with hormone-refractory prostate cancer (n=2). Overall, INCB7839 does exhibit a pro-coagulant effect in some adult patients, resulting in an increased incidence of DVT, whether used alone or in combination. The mechanism of this effect is unknown, and there is no clear relationship between the frequency of thrombosis and the dose administered.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a phase I study and we will use a design similar to the Rolling-6 design and open 6 slots initially on Dose level 1. If we observe no-more than 1 DLT in these 6 subjects then we would expand this cohort to at least 12 patients for PK and additional safety information. If more than 1 DLT is observed on dose level 1 in 2-6 subjects, then further enrollment to dose level 1 will stop, the dose will be de-escalated to dose level 0 and the same approach will be repeated. Based on the above-outlined de-escalation rules, if dose level 0 is found to be too toxic, then the trial will be closed to accrual and the merits of amending or closing the trial permanently will be reconsidered.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
Actual Study Start Date : May 27, 2020
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : December 31, 2023


Arm Intervention/treatment
Experimental: Dose-finding
INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
Drug: INCB7839
INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).




Primary Outcome Measures :
  1. To evaluate the incidence of INCB7839 treatment-emergent adverse events in children with recurrent/progressive High-Grade Gliomas. [ Time Frame: Up to 30 days post treatment. ]
    Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.

  2. Maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839. [ Time Frame: Up to 30 days post treatment. ]
    To estimate the maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839 administered orally in children with recurrent/progressive high-grade glioma.

  3. To characterize the area under the plasma concentration versus time curve (AUC) of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 3 days after the first dose in Course 1. ]
    The area under the curve (AUC) will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.

  4. To characterize the maximum concentration [CMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 3 days after the first dose in Course 1. ]
    The maximum concentration [CMAX] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.

  5. To characterize the apparent oral clearance [CL/F] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 3 days after the first dose in Course 1. ]
    The apparent oral clearance [CL/F] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.

  6. To characterize the time to reach CMAX [TMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 3 days after the first dose in Course 1. ]
    The time to reach CMAX [TMAX] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.


Secondary Outcome Measures :
  1. To make a preliminary assessment of progression-free survival in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 2 years following last dose of INCB7839. ]
    The progression-free survival will be reported.

  2. To make a preliminary assessment of overall survival in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 2 years following last dose of INCB7839. ]
    The overall survival will be reported.

  3. To make a preliminary assessment of duration of response in children with recurrent/progressive high-grade glioma. [ Time Frame: Up to 2 years following last dose of INCB7839. ]
    The duration of response will be reported.


Other Outcome Measures:
  1. ADAM10 inhibition of HER2 extracellular domain in serum. [ Time Frame: Course 1 (up to 28 days after the first dose). ]
    HER2 extracellular domain in serum will be reported.

  2. To assess and monitor ADAM10 inhibition of neuroligin-3 (NLGN3) in cerebral spinal fluid. [ Time Frame: Up to 30 days post treatment. ]
    Neuroligin-3 (NLGN3) in cerebral spinal fluid will be reported.

  3. To characterize the maximum concentration [CMAX] of INCB7839 in cerebrospinal fluid. [ Time Frame: Up to 30 days post treatment. ]
    The maximum concentration [CMAX] will be calculated based on the CSF pharmacokinetic samples.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic diagnosis Patients with recurrent/progressive high-grade gliomas, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR a 25% increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis utilizing the MRI sequence best demonstrating tumor, OR the appearance of a new/metastatic tumor lesion since diagnosis.

    • Eligible diagnoses include but are not limited to the following: diffuse intrinsic pontine glioma (DIPG), H3K27M-mutant diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma and anaplastic oligodendroglioma. Spinal cord tumors are eligible with pathologic confirmation of the above.
    • Please note: patients with a radiographically typical DIPG at diagnosis, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
    • Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of pontine glioma WHO II-IV.
    • Patients with diffuse or multi-focal disease are eligible; patients with leptomeningeal spread are eligible.
  • Age Patient must be ≥ 3 but ≤21 years of age at the time of enrollment.
  • BSA Patients must have a BSA ≥ 0.70-2.50 m2 for dose 120 mg/m2/dose BID. Patients must have a BSA ≥ 0.55-2.80 m2 for dose 80 mg/m2/dose BID (Patients who have BSA 0.55-1.00 m2 will only receive 100 mg AM dose).
  • Ability to Swallow Patient must be able to swallow tablets whole.
  • Measurable disease Patient must have measurable disease in two dimensions on MRI to be eligible.
  • Prior Therapy Patients must have recovered from the acute treatment-related toxicities (defined as < grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment on this study.

Chemotherapy Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.

Investigational/ Biologic Agent

• Biologic or investigational agent (anti-neoplastic): Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment.

o For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.

• Monoclonal antibody treatment and agents with known prolonged half-lives: Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the agent ≥ 28 days prior to study enrollment.

• Immunotherapies: Patients who have received checkpoint inhibitors or other immunotherapies with a known potential for pseudoprogression and who have assumed tumor progression must be at least 3 months from prior immunotherapy AND have at least two MRI scans at least 4 weeks apart demonstrating further progression OR have a biopsy to confirm tumor progression OR have new site(s) of disease.

Radiation

Patients must have had their last fraction of:

  • Craniospinal irradiation, whole brain radiation, total body irradiation or radiation to ≥ 50% of pelvis or spine ≥ 42 days prior to enrollment.
  • Focal irradiation ≥ 14 days prior to enrollment.
  • Local palliative irradiation to site other than primary tumor progression site ≥ 14 days prior to enrollment

Stem Cell Transplant

Patient must be:

  • ≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence of active graft vs. host disease
  • ≥ 3 months since autologous stem cell transplant prior to enrollment

    -- Neurologic Status

  • Patients with neurological deficits should have deficits that are stable for a minimum of 7 days prior to enrollment.
  • Patients with seizure disorders may be enrolled if seizures are well controlled.

    • Performance Status Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50.
    • Organ Function

Patients must have adequate organ and marrow function as defined below:

  • Absolute neutrophil count ≥ 1.0 x 109 cells/ L
  • Platelets >100 x 109 cells/ L (unsupported, defined as no platelet transfusion within 7 days)
  • Hemoglobin ≥ 8g/dl (may receive transfusions)
  • Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
  • ALT (SGPT) and AST (SGOT) < 3 x institutional upper limit of normal (ULN)
  • Albumin ≥ 2 g/dL
  • Serum creatinine based on age/gender as noted in institutional normal range. Patients that are not within institutional normal range but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m2 are eligible.

    • Corticosteroids Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 7 days prior to enrollment.
    • Growth Factors Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (e.g. filgrastim, sargramostim or erythropoietin). 14 days must have elapsed if patient received a long-acting formulation.
    • Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
    • Informed Consent The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.
    • HIV Positive Patients

HIV-positive patients are eligible if the following criteria are met:

  • Stable on their antiretroviral agents
  • Have CD4 counts above 400/mm3
  • Undetectable viral loads, and
  • No need for prophylactic medications for an opportunistic infections

Exclusion Criteria:

  • Pregnancy or Breast-feeding Pregnant women or nursing mothers are excluded from this study. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    • Pregnant or breast-feeding women are excluded from this study due to risks of fetal and teratogenic adverse events as seen in animal studies.

  • Concurrent Illness

    • Patients with any clinically significant unrelated systemic illness (e.g., serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
    • Patients with any other current malignancy.
  • Concomitant Medications

    • Patients who are receiving any other anti-cancer, investigational or alternative (e.g. cannabinoids) drug therapy are ineligible.

  • Prisoners Prisoners will be excluded from this study.
  • Inability to participate Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures and study restrictions.
  • Allergy Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition.
  • Thrombosis Risk

    • Patients with a known coagulopathy or bleeding disorder (e.g., von Willebrands disease) are not eligible.
    • Patients with a history of non-central line related thrombosis or disorders that promote clotting (e.g., anti-thrombin III deficiency, Lupus anticoagulant) are not eligible.
    • Significant family history of thrombosis (i.e. deep venous thrombosis or pulmonary embolus) in a first-degree relatives (i.e., parents or siblings) are not eligible.

Family history must be documented to the best extent it is known.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04295759


Contacts
Layout table for location contacts
Contact: Shujie Han (901) 595-4877 shujie.han@stjude.org

Locations
Layout table for location information
United States, California
Children's Hospital Los Angeles Not yet recruiting
Los Angeles, California, United States, 90026
Contact: Nathan Robison, MD    323-361-8147    nrobison@chla.usc.edu   
Principal Investigator: Nathan Robison, MD         
Lucile Packard Children Hospital Stanford University Not yet recruiting
Palo Alto, California, United States, 94304
Contact: Michelle Monje    650-721-5750    mmonje@stanford.edu   
United States, Colorado
Children's Hospital Colorado Not yet recruiting
Aurora, Colorado, United States, 80045
Contact: Kathleen Dorris    720-777-1234    kathleen.dorris@childrenscolorado.org   
United States, District of Columbia
Children's National Medical Center Not yet recruiting
Washington, District of Columbia, United States, 20010
Contact: Eugene Hwang, M.D.    202-476-5046    ehwang@childrensnational.org   
Contact: Sabrina Malik    202-476-5115    smalik@childrensnational.org   
Principal Investigator: Eugene Hwang, M.D.         
United States, Georgia
Children's Healthcare of Atlanta Not yet recruiting
Atlanta, Georgia, United States, 30322
Contact: Jason Fangusaro    404-785-5437    jfangus@emory.edu   
United States, Illinois
Lurie Childrens Hospital-Chicago Not yet recruiting
Chicago, Illinois, United States, 60614
Contact: Stewart Goldman    312-227-4874    sgoldman@luriechildrens.org   
Principal Investigator: Stewart Goldman, MD         
United States, Maryland
National Cancer Institute Pediatric Oncology Branch Not yet recruiting
Bethesda, Maryland, United States, 20892
Contact: John Glod, MD    301-451-0391    john.glod@nih.gov   
Principal Investigator: John Glod         
United States, Massachusetts
Dana Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Katherine Warren    617-632-4907    katherinee_warren@dfci.harvard.edu   
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Ira Dunkel    212-639-2153    dunkeli@mskcc.org   
Principal Investigator: Ira Dunkel         
United States, Ohio
Cincinnati Children Hospital Medical Center Not yet recruiting
Cincinnati, Ohio, United States, 45229
Contact: Mariko D DeWire-Schottmiller, MD    513-636-1849    mariko.dewire@cchmc.org   
Principal Investigator: Mariko D DeWire-Schottmiller, MD         
United States, Pennsylvania
Children Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Ian Pollack    412-692-5881    Pollaci@chp.edu   
Principal Investigator: Ian Pollack         
United States, Tennessee
St. Jude Children Research Hospital Not yet recruiting
Memphis, Tennessee, United States, 38105
Contact: Giles Robinson, MD    901-595-2907    giles.robinson@stjude.org   
Sub-Investigator: Amar Gajjar, MD         
United States, Texas
Baylor College of Medicine Not yet recruiting
Houston, Texas, United States, 77030
Contact: Patricia Baxter, MD    832-824-4681    pabaxter@txch.org   
Contact: Susan Burlingame, CCRP    832-824-1532    sxburlin@txch.org   
Principal Investigator: Patricia Baxter, MD         
Sponsors and Collaborators
Pediatric Brain Tumor Consortium
Investigators
Layout table for investigator information
Study Chair: Michelle Monje Stanford University and Lucile Packard Children's Hospital
Layout table for additonal information
Responsible Party: Pediatric Brain Tumor Consortium
ClinicalTrials.gov Identifier: NCT04295759    
Other Study ID Numbers: PBTC-056
First Posted: March 4, 2020    Key Record Dates
Last Update Posted: May 28, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Glioma
Astrocytoma
Oligodendroglioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue